Table 1 Base case analysis results over a lifetime horizon.

From: Cost-effectiveness analysis of COPD screening programs in primary care for high-risk patients in China

Strategies

No screening/usual care (A)

Questionnaire screening (B)

Portable spirometer screening (C)

Costs (¥)

24,725

24,307

24,078

Life years

2.10

2.57

2.64

QALY

1.37

1.69

1.74

Incremental analysis

B vs. A

C vs. B

C vs. A

Δ Cost (¥)

−419

−229

−647

Δ QALY

0.32

0.05

0.37

ICER

−1,304 dominant

−5,026 dominant

−1,766 dominant

  1. QALY Quality-adjusted life years; ICER Incremental cost-effectiveness ratio.
Back to article page